#United States #Kessler Topaz #Securities Fraud #Radnor #Zoetis

Investor Alert: Zoetis Inc. Under Fire for Securities Fraud

Kessler Topaz Meltzer & Check, LLP, a renowned U.S. law firm specializing in securities litigation, has announced a major development regarding Zoetis Inc., a leading animal health company known for its veterinary products. A securities fraud class action lawsuit has been filed against Zoetis, impacting all investors who acquired its securities between January 14, 2025, and May 6, 2026. This legal action brings to light serious allegations that could have significant implications for investors.

The lawsuit was officially filed in the Southern District of New York and is titled City of Ann Arbor Retiree Health Care Benefit Plan Trust v. Zoetis Inc. The allegations include that investors were misled by material misstatements and omissions regarding the company’s business operations and product performance. Particularly, claims suggest that Zoetis made false representations about the growth of its prescription products and failed to disclose crucial information that might have affected investor decisions.

Among the key complaints, one major point of contention involves Librela, a popular pain treatment for dogs, where growth was reportedly stalling after the FDA issued safety warnings due to serious neurological side effects. Also troubling is the market performance of Simparica Trio, a preventative for fleas and ticks, which allegedly began losing significant market share to lower-priced alternatives. Furthermore, its dermatological products, Apoquel and Cytopoint, are also said to have been underperforming against competitor products. These issues led to a significant drop in investor confidence.

The situation intensified on May 7, 2026, when Zoetis announced its first-quarter financial results, revealing a major decline in its Companion Animal segment. This news resulted in a staggering 21.5% fall in the company's stock price, causing alarm among its investors. Kessler Topaz encourages individuals who purchased Zoetis securities and suffered financial losses to consider their legal options proactively.

The deadline for affected investors to apply for lead plaintiff status in this class action lawsuit is July 27, 2026. Engaging with Kessler Topaz Meltzer & Check, LLP could provide investors with essential insights into potential recovery routes available to them. The firm specializes in representing investors and has a history of securing over $25 billion in recovery for its clients.

For those looking for guidance, Kessler Topaz offers complimentary consultations regarding the lawsuit. Notably, there is no financial obligation for initial discussions, providing a risk-free opportunity for investors to assess their legal standing.

How to Take Action

Investors holding ZTS securities are advised to act swiftly. The options include:

• - File for Lead Plaintiff Status: Ensure to submit your application by the deadline if you wish to represent the interests of the class.
• - Contact Kessler Topaz Meltzer & Check, LLP: For a free case evaluation, reach out to their office directly. Their team, including experienced attorney Jonathan Naji, is prepared to discuss your situation without any charges involved.

Kessler Topaz has a record of advocating fiercely in cases of securities fraud, emphasizing investor rights and helping recover damages for those affected. Understanding the details of the lawsuit and possible outcomes can empower investors to make informed decisions.

For more information on this matter, visit Kessler Topaz Meltzer & Check or directly reach out to attorney Jonathan Naji at (484) 270-1453. Stay informed, take action, and safeguard your investment interests.

About Kessler Topaz Meltzer & Check, LLP

Founded as a dedicated plaintiff-side law firm, Kessler Topaz Meltzer & Check, LLP (KTMC) focuses on securities fraud class actions and has built a strong reputation for protecting investor rights. With multiple accolades and a global presence, KTMC continues to stand at the forefront of investor protection efforts, advocating for individual and institutional investors alike.